CAMBRIDGE, Mass., Aug. 28, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced that new clinical data on the inhibition of PSCK9* by its oral SMART Linker conjugate, CAT-2003, will be presented at the Physicians Academy for Continuing Education (PACE) conference in Amsterdam on Aug. 31 by Catabasis' chief medical officer, Joanne Donovan, M.D., Ph.D., during the "Novel interventions in cardiovascular disease: Controversies & hot issues" session. The presentation will include results from CAT-2003's recently completed Phase 1 trial.
Details of the presentation follow:
- Joanne Donovan, M.D., Ph.D. - "A novel approach to target fasting and post-prandial triglycerides." Physicians Academy for Continuing Education (PACE) conference, Novel interventions in cardiovascular disease: Controversies & hot issues session. Novotel Amsterdam City, Amsterdam. Saturday, Aug. 31, 12:00-12:10 p.m. CEST.
* PCSK9 proprotein convertase subtilisin/kexin type 9
CAT-2003 is a new chemical entity that is a SMART Linker conjugate. It is being investigated for the treatment of severe hypertriglyceridemia. In preclinical models of severe hypertriglyceridemia, a significant and dose-dependent reduction in plasma triglycerides was observed with CAT-2003. In preclinical models of dyslipidemia, CAT-2003 reduced low density lipoprotein cholesterol (LDL-C) cholesterol. In combination with a statin, CAT-2003 synergistically lowered LDL-C cholesterol. In a Phase 1 trial, CAT-2003 demonstrated a significant reduction in fasting and post-prandial triglyceride levels and had positive effects on biomarkers including reductions in LDL-C, apolipoprotein C-III (ApoC-III), apolipoprotein B (ApoB) and PCSK9.
Catabasis is a clinical-stage company dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway to produce new chemical entities with significantly enhanced efficacy and an improved safety and tolerability profile. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.
Please visitwww.catabasis.com for more information.
SOURCE Catabasis Pharmaceuticals, Inc.